QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) and TumorGenesis Advancing Path Toward Patient-Specific Treatments
Predictive Oncology (NASDAQ: POAI), together with its TumorGenesis subsidiary, has achieved significant breakthroughs in applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. Earlier in June, TumorGenesis, which is developing a new rapid approach to growing tumors in the laboratory, sold its first order of unique ovarian cancer cell culture media to a New England-based university carrying out research within the sector (http://ibn.fm/lpsCk). A recent article discussing POAI and TumorGenesis reads, “Predictive Oncology focuses on building AI-driven predictive models of tumor drug response and outcomes from its database of drug-response and genomic profiles gathered from more than 150,000…